Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;264(5):1023-1028.
doi: 10.1007/s00415-016-8336-4. Epub 2016 Nov 22.

Neurosarcoidosis: a clinical approach to diagnosis and management

Affiliations
Review

Neurosarcoidosis: a clinical approach to diagnosis and management

Richard T Ibitoye et al. J Neurol. 2017 May.

Abstract

Sarcoidosis is a rare but important cause of neurological morbidity, and neurological symptoms often herald the diagnosis. Our understanding of neurosarcoidosis has evolved from early descriptions of a uveoparotid fever to include presentations involving every part of the neural axis. The diagnosis should be suspected in patients with sarcoidosis who develop new neurological symptoms, those presenting with syndromes highly suggestive of neurosarcoidosis, or neuro-inflammatory disease where more common causes have been excluded. Investigation should look for evidence of neuro-inflammation, best achieved by contrast-enhanced brain magnetic resonance imaging and cerebrospinal fluid analysis. Evidence of sarcoidosis outside the nervous system should be sought in search of tissue for biopsy. Skin lesions should be identified and biopsies taken. Chest radiography including high-resolution computed tomography is often informative. In difficult cases, fluorodeoxyglucose positron emission tomography and gallium-67 imaging may identify subclinical disease and a target for biopsy. Symptomatic patients should be treated with corticosteroids, and if clinically indicated other immunosuppressants such as hydroxychloroquine, azathioprine, cyclophosphamide or methotrexate should be added. Anti-tumour necrosis factor alpha therapies may be considered in refractory disease but caution should be exercised as there is evidence to suggest they may unmask disease.

Keywords: Diagnosis; Management; Neurosarcoidosis; Sarcoidosis; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

None of the authors has any conflict of interest in relation to the material in this manuscript.

Ethical standard statement

The manuscript does not contain clinical studies or patient data.

References

    1. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7(4):234–244. doi: 10.1136/jnnp.2007.124263. - DOI - PubMed
    1. Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, et al. Central nervous system sarcoidosis—diagnosis and management. QJM. 1999;92(2):103–117. doi: 10.1093/qjmed/92.2.103. - DOI - PubMed
    1. Wessendorf TE, Bonella F, Costabel U. Diagnosis of sarcoidosis. Clin Rev Allergy Immunol. 2015;49(1):54–62. doi: 10.1007/s12016-015-8475-x. - DOI - PubMed
    1. Rybicki BA, Major M, Popovich J, Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–241. doi: 10.1093/oxfordjournals.aje.a009096. - DOI - PubMed
    1. Mayock RL, Bertrand P, Morrison CE, Scott JH. Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med. 1963;35:67–89. doi: 10.1016/0002-9343(63)90165-7. - DOI - PubMed

MeSH terms

Supplementary concepts